CAC
VIR icon

Cowen and Company’s Vir Biotechnology VIR Stock Holding History

Cowen and Company’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,000
Closed -$13K – 756
2021
Q3 		$13K Buy
+3,000
New +$130K ﹤0.01% 513

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.57B AUM 15.23% 1-Year Est. Return

Cowen and Company's VIR Position: Q4 2021 in Review

Cowen and Company sold out of Vir Biotechnology (VIR) in Q4 2021, closing a stake of 10,850 shares — an estimated $472K sold.

Cowen and Company first reported a position in VIR in Q3 2021 and held it in 1 quarter. The position peaked at $472K in Q3 2021. 210 funds tracked by Wall St. Rank hold VIR as of Q4 2021.

  • Cowen and Company reported no remaining Vir Biotechnology position as of Q4 2021 after selling out during the quarter.
  • Cowen and Company sold 10,850 Vir Biotechnology shares in Q4 2021, an estimated $472K.
  • Cowen and Company first reported a position in Vir Biotechnology in Q3 2021 and held it in 1 quarter.
  • Cowen and Company's Vir Biotechnology position peaked at $472K in Q3 2021.
  • 210 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2021.

Based on Cowen and Company's 13F filing for Q4 2021, filed 14 Feb 2022.